We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01814748
First Posted: March 20, 2013
Last Update Posted: August 29, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
Results First Submitted: June 7, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Diabetes Mellitus
Interventions: Drug: Omarigliptin
Drug: Placebo to omarigliptin
Drug: Metformin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Omarigliptin 25 mg Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
Placebo Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.

Participant Flow:   Overall Study
    Omarigliptin 25 mg   Placebo
STARTED   102   101 
COMPLETED   94   94 
NOT COMPLETED   8   7 
Lost to Follow-up                1                2 
Study site terminated by sponsor                1                1 
Withdrawal by Subject                6                4 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Omarigliptin 25 mg Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
Placebo Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
Total Total of all reporting groups

Baseline Measures
   Omarigliptin 25 mg   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 102   101   203 
Age 
[Units: Years]
Mean (Standard Deviation)
 38.8  (4.7)   39.5  (4.5)   39.2  (4.6) 
Gender 
[Units: Participants]
     
Female   35   41   76 
Male   67   60   127 
Hemoglobin A1c (A1C) 
[Units: Percent]
Mean (Standard Deviation)
 7.9  (0.8)   8.1  (0.9)   8.0  (0.8) 
2-hour post-meal glucose (2-hr PMG) [1] 
[Units: mg/dL]
Mean (Standard Deviation)
 204.9  (55.1)   217.3  (67.7)   211.2  (62.0) 
[1] Participants with available data at baseline: Omarigliptin, n=98; Placebo, n=101; Total, n=199
Fasting plasma glucose (FPG) 
[Units: mg/dL]
Mean (Standard Deviation)
 164.0  (38.9)   167.8  (40.6)   165.9  (39.7) 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in A1C at Week 24   [ Time Frame: Baseline and Week 24 ]

2.  Primary:   Percentage of Participants Who Experienced at Least One Adverse Event (AE)   [ Time Frame: Up to Week 27 ]

3.  Primary:   Percentage of Participants Who Discontinued Study Drug Due to an AE   [ Time Frame: Up to Week 24 ]

4.  Secondary:   Change From Baseline in 2-hr PMG at Week 24   [ Time Frame: Baseline and Week 24 ]

5.  Secondary:   Change in Baseline in FPG at Week 24   [ Time Frame: Baseline and Week 24 ]

6.  Secondary:   Percentage of Participants Attaining A1C Glycemic Goals of <7.0% at Week 24   [ Time Frame: Week 24 ]

7.  Secondary:   Percentage of Participants Attaining A1C Glycemic Goals of <6.5% (48 mmol/Mol) at Week 24   [ Time Frame: Week 24 ]

8.  Secondary:   Percentage of Participants Who Required Glycemic Rescue by Week 24   [ Time Frame: Up to Week 24 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Investigations indicate that the presence of metformin in future biomedical research (FBR) samples from non-rescued participants was due to participant self-administration of metformin outside of the protocol and without investigator knowledge.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp.
phone: 1-800-672-6372
e-mail: ClinicalTrialsDisclosure@merck.com



Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01814748     History of Changes
Other Study ID Numbers: 3102-028
2012-004303-12 ( EudraCT Number )
First Submitted: March 18, 2013
First Posted: March 20, 2013
Results First Submitted: June 7, 2016
Results First Posted: July 18, 2016
Last Update Posted: August 29, 2016